Product logins

Find logins to all Clarivate products below.


BGB-16673

Learn how BGB-16673 is changing the chronic lymphocytic leukemia (CLL)/
small lymphocytic leukemia (SLL) landscape.

What is BGB-16673 and what sets it apart

BGB-16673 is a potential first-in-class targeted protein degrader that is designed to promote the degradation of both wild-type and mutant forms of Bruton tyrosine kinase (BTK), including those that commonly cause resistance in progressive disease.

Early clinical data support the strong preclinical profile, and if approved, it has the potential to be a paradigm-changing treatment for B-cell malignancies. Although its development is most advanced for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), its dual capability to degrade wild-type and resistant BTK means it could be effective in multiple indications within hematological cancers.

About BGB-16673

  • Company: BeOne Medicines
  • Type: BTK-targeting chimeric degradation activation compound (CDAC)
  • Usage: Once-daily oral administration to treat relapsed or refractory CLL or SLL
    Also being investigated for relapsed or refractory Waldenstrom’s macroglobulinemia (WM), other relapsed or refractory B-cell malignancies including mantle cell lymphoma (MCL) and follicular lymphoma (FL), and chronic spontaneous urticaria (CSU)
  • When will BGB-16673 be available?
    Expected launch 2027: European Union, United States
    Expected launch 2029: Japan

BGB-16673 sales and success forecasts

$1.19bn
expected sales in the G7 markets in 2031
81%
probability of success for BGB-16673 in the European Union

BGB-16673 could be a revolution in the treatment of CLL/SLL. The efficacy is impressive, especially since it's a double or triple-refractory population, and the safety seems very similar to BTK inhibitors.

Hematologist-oncologist Italy

Drugs in the 2026 list

Related insights

Protein degraders enabling precision interventions for “undruggable” targets Protein degraders enabling precision interventions for “undruggable” targets
Report
Protein degraders enabling precision interventions for “undruggable” targets

Six innovators at the forefront of the emerging field of protein degrader development.

Targeting the “Undruggable”: Emerging Degrader Modalities for Novel Target Identification and Validation Targeting the “Undruggable”: Emerging Degrader Modalities for Novel Target Identification and Validation
Webinar
Targeting the “Undruggable”: Emerging Degrader Modalities for Novel Target Identification and Validation

A significant portion of disease-relevant proteins remain “undruggable” by traditional therapeutic approaches, representing a major hurdle in drug discovery. Targeted protein degradation (TPD) is rapidly advancing as a strategy to overcome this challenge, enabling the selective elimination of previously inaccessible proteins. In this on-demand webinar, experts from Clarivate, Nurix Therapeutics, Triana, and Monte Rosa Therapeutics...

Pharma is placing bigger bets on fewer, more strategic assets/platforms Pharma is placing bigger bets on fewer, more strategic assets/platforms
Blog May 28, 2025
Pharma is placing bigger bets on fewer, more strategic assets/platforms

Looming patent cliffs drove the highest recorded deal values in 2024, as pharmas continued a strategic shift towards making fewer but higher-stakes transactions. However, geopolitical uncertainty has put a damper on investment.

chevron_left
chevron_right